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Prospects & Overviews
Mouse models of colorectal cancer as
preclinical models
Rebecca E. McIntyre1), Simon J.A. Buczacki2), Mark J. Arends3) and David J. Adams1)
In this review, we discuss the application of mousemodels
to the identification and pre-clinical validation of novel
therapeutic targets in colorectal cancer, and to the search
for early disease biomarkers. Large-scale genomic, tran-
scriptomic and epigenomic profiling of colorectal carci-
nomas has led to the identification of many candidate
genes whose direct contribution to tumourigenesis is yet
to be defined; we discuss the utility of cross-species
comparative omics-based approaches to this problem.We
highlight recent progress in modelling late-stage disease
using mice, and discuss ways in which mouse models
could better recapitulate the complexity of human cancers
to tackle the problem of therapeutic resistance and
recurrence after surgical resection.
Keywords:.colorectal cancer; disease biomarker; mouse model;
ome and omics; target identification; target validation
Introduction
Colorectal cancer (CRC) accounts for 700,000 deaths and 1.4
million newly diagnosed cases globally per annum, making it
the number one cause of non-smoking related cancer
deaths [1]. Most CRCs arise in the epithelium, a process
driven by genetic and/or epigenetic alterations that result in
the formation of premalignant lesions called adenomas (see
Table 1 for list of genes most frequently mutated in CRCs).
The transition from normal epithelium to benign adenoma
is initially driven by alterations that hyperactivate the Wnt
pathway (>95% CRCs), and this predominantly occurs
through inactivation of the APC gene (>80% CRCs) [2–4].
APC is a negative regulator of the Wnt pathway and
hyperactivation of the Wnt pathway is critical to both the
initiation and maintenance of the vast majority of CRCs,
although pathway activation is finely tuned [2, 5, 6]. For
example, alteration of many genes that are known to
regulate Wnt signalling, such as AXIN2 (Axis inhibition
protein 2) and AMER1 (APC membrane recruitment 1) are
found in tumours that also harbour APC mutations [2, 7].
The Wnt pathway is also critical for the maintenance of the
intestinal epithelium, which undergoes complete renewal
every 4–5 days in humans [8]; therefore, it has not been
possible to target this pathway in cancers without disrupting
intestinal regeneration [9].
Activation of the Ras-MAPK (Kirsten rat sarcoma viral
oncogene homolog and mitogen activated protein kinase)
pathway, usually via point mutations that constitutively
activate KRAS or BRAF (v-raf murine sarcoma viral oncogene
homolog B), and inactivation of the TGFb (transforming
growth factor b) pathway through inactivation of SMAD gene
family members or TGFb receptors, promote the development
of advanced adenomas or invasive adenocarcinomas [3]. Over
time, a small proportion of advanced adenomas acquire
further molecular abnormalities that transform them to
invasive and then metastatic carcinomas. Inactivation of
TP53 (Tumour protein p53) or IGF2R (Insulin-like growth
factor 2 receptor) occurs with greater frequency in established
carcinomas that invade submucosal layers than in adeno-
mas [3, 10]. However the molecular alterations that support
metastases are poorly understood; at the genomic level at
least, it would appear that there is high concordance between
primary CRCs and their matched metastatic lesions, which
suggests that mechanisms other than gene mutation may be
responsible for progression tometastatic disease—for example
epigenetic or post-translational modifications [10–12].
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Endoscopic or surgical resection is routinely used for patients
with early premalignant adenomas, as well as for the
treatment of most early stage carcinomas and selected
patients with late stage or advanced metastatic disease, for
whom chemotherapy (or radiotherapy/chemoradiotherapy for
rectal cancers) is also a key treatment modality [13]. Liver
metastases of colorectal carcinomas occur in about 50% of
patients, either at the time of diagnosis or at recurrence, and
this is a major cause of CRC-related deaths [13]. Long-term
survival of CRC patients is correlated with disease stage at
diagnosis, and the 5-year survival rate for patients with
metastatic CRC is less than 10% [14].
Aside from our lack of understanding of the molecular
events that drive metastases, there are several other plausible
explanations for our limited success in treating CRC. Firstly,
there are currently few biomarkers that are predictive of early
disease, the likelihood of favourable treatment response,
recurrence or the development of metastatic disease [10].
Secondly, therapeutic resistance, be it acquired or intrinsic, to
several licensed colorectal cancer therapies is a major
problem [15]. For example, overexpression of the epidermal
growth factor (EGF) receptor is associated with increased
metastatic potential and poor prognosis in CRC. In these
subgroups of cancer patients, monoclonal antibodies to the
EGF receptor e.g. Cetuximab and Panitumumab, block EGF
binding and result in tumour regression [16, 17]. Resistance to
therapy eventually develops through a variety of mechanisms
including point mutations in the EGF receptor that inhibit
Cetuximab binding but not EGF, or activating mutations in
KRAS, an intracellular signalling pathway that converges with
the EGF receptor pathway. Finally, the drug discovery pipeline
attrition rate for oncology investigational compounds is
extremely high. Only 5% of compounds that show promise
in pre-clinical studies are eventually approved for clinical use
as the majority fail in Phase I/II trials [18]. One of the reasons
for this may be the extensive use of CRC cell lines and
xenograft models derived from them in pre-clinical anti-
cancer drug testing (reviewed by [18, 19]). Cell culture does not
model the interaction of primary tumour cells with surround-
ing cells (the tumour microenvironment or stroma), the
process of organ colonisation by metastatic cancer cells (the
‘seed and soil’ hypothesis), and the recruitment and activation
of the adaptive and innate immune systems during tumouri-
genesis, which are known to exert selective pressures on
cancer cells [20–22]. Several cell culture systems have been
developed to make allowances for reciprocal cell communi-
cation; examples include organoid cultures, the co-culture of
tumour epithelial cells and stromal cells or three-dimensional
Table 1. Selection of some of the most frequently mutated genes in colorectal cancer
Human/mouse
gene symbol
Frequency
(%) Full gene name Role in development of CRC
APC/Apc >80 Adenomatous
Polyposis Coli
• Inactivation of APC is the initiating event in the majority of colorectal
cancers [100]
• APC is a negative regulator of the Wnt pathway
• Hyperactivation of the Wnt pathway initiates development of CRC by
stabilising the b-catenin transcription factor, increasing expression of
transcription factors such as c-Myc and c-Fos, which regulate
expression of cell cycle genes
TP53/Trp53 65 Tumor protein p53 • Loss of TP53 is associated with disease progression [101]
• TP53 regulates expression of genes that induce cell cycle arrest,
apoptosis, senescence, DNA repair, or changes in metabolism
KRAS/Kras
BRAF/Braf
45
8
Kirsten rat sarcoma
viral oncogene
homolog
v-raf murine sarcoma
viral oncogene
homolog B
• Mutation of KRAS (>75% of mutations are at codon 12) and BRAF
cause activation of the Ras-MAPK pathway and mutations in these
genes are mutually exclusive [2]
• Activation of Ras-Mapk pathway is associated with disease
progression and poor prognosis [102]
• Activation of the Ras-MAPK pathway leads to activation of
transcription factors such as c-Myc, and c-Fos, which in turn regulate
expression of cell cycle genes
FBXW7/Fbxw7 20 F-Box And WD
Repeat Domain
Containing 7
• E3 ubiquitin ligase that targets cyclin E and c-Myc (cell cycle
regulators) for ubiquitin-mediated degradation [103]
• Low expression of FBXW7 is associated with poor prognosis [104]
TGFBR2/Tgfbr2
SMAD2/Smad2
SMAD3/Smad3
SMAD4/Smad4
12
7
5
12
Transforming growth
factor, beta receptor 2
SMAD family member
2, 3, 4
• Alterations in TGFb pathway e.g. mutation of TGFBR2, SMAD2,
SMAD3 and SMAD4, are associated with disease progression [93, 105]
• The SMAD family are intracellular signal transducers that are
activated by TGFb receptors and act as transcriptional modulators.
PTEN/Pten 10 Phosphatase and
tensin homolog
• PTEN dephosphorylates phosphoinositide substrates and negatively
regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate
(PIP3)
• Negatively regulates AKT/PKB signaling pathway
CDK8/Cdk8 12 Cyclin dependent
kinase 8
• CDK8 regulates the cell cycle by acting as a co-activator for
transcription of nearly all RNA Polymerase II-dependent genes
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cultures [23–25]. While these systems provide important
insights into disease biology, they are limited in their
ability to model the dynamic interplay between tumour and
host. In this review, we summarise the strengths and
weaknesses of xenograft models derived from CRC cell
lines and primary patient derived material, and genetically
modified mouse models of colorectal cancer. We discuss
several novel applications of these models in cancer gene
validation, biomarker discovery and target validation, and
discuss their future roles in cross-species comparative ‘omics’
approaches to understanding metastasis and therapeutic
resistance.
Cell line xenografts for reductionist
target validation
Xenografting involves the injection of cells or the surgical
transplantation of primary tissue into immune-deficient mice
such as the nude mouse, which is athymic and does not
produce T-lymphocytes, or the severe combined immune-
deficient (SCID) mouse, which has altered adaptive immunity
but normal innate immunity, to prevent rejection. It was
thought that the large number of commercial colorectal cell
lines available would represent the inter-tumour heteroge-
neity of the human disease, but in reality, few cell lines lead to
reliable primary tumour growth, and fewer still to naturally
metastatic CRC [26]. Success rates appear to be highest when
using the colorectal carcinoma cell lines HCT-116 or HT-29, but
it is not yet clear why this is. Xenograft models are useful
for rapid, reductionist, target validation studies, including
validation of the many candidate cancer genes identified by
The Cancer GenomeAtlas (TCGA), however the results must be
interpreted with caution (Table 2, Fig. 1 [27, 28]). For example,
the environment of subcutaneous tumours is very different
from that of autochthonous colorectal carcinomas (i.e.
tumours that originate in the location where they are found)
and liver metastases; and the extent to which the species
mismatch in tumour (human) and stromal (mouse) cells
influence tumour growth in vivo is uncertain. CRC stroma
is composed of macrophages that secrete matrix-degrading
factors such as metalloproteinases, myofibroblasts that
secrete Wnt ligands, T-cells that secrete proinflammatory
cytokines, and endothelial cells and bone-marrow derived
cells, all of which contribute greatly to the growth and
progression of this tumour type [20, 22, 29].
Orthotopic xenografts of CRC cell lines
improve tumour-stromal cell cross-talk
and the reproducibility of liver
metastases
Microenvironmental differences likely explain why the
morphology of subcutaneous CRC cell line xenografts,
especially the stromal elements, are often markedly different
from the human disease and may explain why they have a low
Table 2. Transplantation models of colorectal cancer (CRC)
Transplantation model Strengths Weaknesses
Subcutaneous CRC cell line
xenograft: injection of cells e.g.
HCT116 and HT29 to immune
deficient mouse
• Low cost
• Rapid tumour growth (2 weeks)
• Well characterized cell-lines: gene
mutation status, transcriptome and drug
response data available [73, 106, 107]
• Easy to genetically manipulate prior to
transplantation e.g. with inducible shRNA
or by CRISPR/Cas9 [108]
• Model accessible to the majority of
research labs
• Representative of advanced disease
• Have undergone significant clonal selection [73]
• Microenvironmental differences (cells derived
from colorectum injected under skin)
• Species mismatch in tumour (human) and
stromal (mouse) cell may limit cross-talk
• Immune deficient host
• Rarely metastasise
Orthotopic xenografts of CRC cell
lines: injection of cells into
intestinal serosa of immune
deficient mouse
• As above
•More natural microenvironment for CRC
cells
• Some metastasise to liver e.g. from
HCT116 or HT29
• As above (except for ‘rarely metastasise’)
• May require surgery to implant cells
Patient-derived xenografts (PDXs):
Suturing of 1–2mm fragments of
fresh surgical specimens of CRC,
to intestine of immune deficient
mouse
• Reproducible liver metastasis
• Avoid selection of dominant clones
during long-term cell culture
• Temporary preservation of species-
specific tumour-stromal cell cross talk
•More natural microenvironment for CRC
cells
• Not readily scalable
• Host (mouse) stromal cells replace human
stromal cells within a few weeks (species
mismatch)
• Immune deficient host
• Limited by availability of surgical specimens
• Expensive (labour intensive and time
consuming)
Syngraft/Isograft: Suturing 1–2mm
mouse tumour fragments or mouse
tumour cell lines e.g. MC38 cells to
a genetically identical inbred,
immune competent mouse
• No species mismatch between tumour
and stromal cells
• Host has intact immune system that
enables testing of immunomodulatory
anti-cancer agents
• Expensive (labour intensive and time
consuming)
• The model is not human
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metastatic potential [30]. In an attempt to improve the utility
of xenograft models, several investigators have systematically
tested different variables and found that CRC cell line, site of
injection, mouse age and the genetic background of themouse
all markedly affect the frequency of lymph-node or liver
metastases [27, 31, 32]. Orthotopic xenografts involve the
injection of differentiated cells to a more natural micro-
environment i.e. the serosa of the intestine for CRC cell lines,
and appears to result inmore reproducible liver metastasis [31,
33]. In addition, orthotopic and subcutaneous xenograft
models show differing sensitivities to chemotherapeutic
agents [30, 31], suggesting that the microenvironment is
important for both disease progression and therapeutic
response. Recent refinements to the caecal
pouch xenograft method include the non-
surgical trans-anal injection of cells into the
distal rectum or the microinjection of cell
lines to the caecum and engineering cells to
express b-human chorionic gonadotropin
to support growth [31, 34].
Patient-derived orthotopic
xenografts temporarily
preserve tumour-stromal cell
cross-talk and improves
reproducibility of metastasis
Patient derived xenografts (or ‘PDXs’) avoid
the natural selection of dominant clones
and epigenetic and genetic alterations that
occur during long-term cell culture as well
as temporarily preserving the original,
species-specific, tumour-stromal cell inter-
actions. The suturing of small fragments of
fresh surgical specimens of CRC liver metastases to the
caecum of immune-deficient mice has been reproducible in
generating models of metastatic CRC [35, 36]. It was thought
that PDXs could be used to test therapies and development of
resistance ahead of patient treatment to help personalize
cancer therapy, however the approach requires subculture or
serial xenografting which currently takes too long [37]. A
number of studies have also now reported that host
cells replace the human stroma and vasculature of patient
derived xenografts, and in the case of CRCs, this appears to
occur relatively rapidly (3 weeks vs. 9 weeks for mesothe-
lioma; [38, 39]).
‘Syngraft’ or ‘Isograft’ models retain
species-specific cross-talk between
tumour, stroma and immune cells
The two major limitations of all xenograft mouse models of
human CRC cell lines are the species mismatch between
tumour and stroma, which likely affects cell communication,
and the use of immune-deficient hosts. The role of the immune
system appears to be particularly important for the develop-
ment of CRC; T cell immune infiltrate is an important
predictive criterion for patient survival [40] and mice with
deletion of Smad4 in T-cells excessively secrete proinflamma-
tory cytokines and develop gastrointestinal tumours [41]. The
use of immune-deficient hosts allows development of tumours
in the absence of an immune infiltrate, which is critical for
CRC tumour progression, and also precludes the testing of
immunomodulatory anti-cancer agents. Grafting tumour
fragments or the cell lines derived from them, for example
MC38 cells (derived from amouse colon adenocarcinoma), to a
genetically identical inbred, immune competent mouse
(‘syngraft’ or ‘isograft’) is a way of overcoming both of these
problems [19].
Figure 1. Mouse models of advanced colorectal cancer (CRC) as
research and preclinical tools. The development of genetically
engineered mouse models (GEMMs) carrying gene mutations that
closely match those found by deep-sequencing of human colorectal
carcinomas provide information on the homeostatic and tumouri-
genic role of a gene in the intestine. Orthotopic transplantation of
select colorectal carcinoma cell lines to the caecum of immune-
deficient mice results in primary tumour growth and metastases to
lymph nodes or liver. Prior to transplantation, colorectal carcinoma
cell lines can be genetically manipulated to overexpress (cDNA
vector) or inhibit (shRNA or CRISPR-Cas9 vector) a gene of interest
to rapidly assess its biological role or to validate potential therapeutic
targets. Introducing a reporter gene, such as green fluorescent
protein (GFP), to cells prior to transplantation allows in vivo
monitoring of primary tumour or metastases growth, which is
extremely useful when assessing responses to pharmacological
agents or inducible genetic manipulation. Single-cell suspensions
from carcinomas can be flow-sorted using cell-specific markers to
identify cells of interest, for example stem-like cells for growth of
organoids, or to gain further insight into the tumour cells of origin
and their interactions with the microenvironment. Cultured cells can
be utilised for drug sensitivity screens. Mouse models of advanced
CRC can be used to screen for cancer driver genes and disease
biomarkers.
R. E. McIntyre et al. Prospects & Overviews....
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Genetically modified mouse models of
colorectal cancer retain species-specific
cross-talk between tumour, stroma and
immune cells
Genetically engineered mouse models (GEMM) offer several
advantages over cancer cell lines as research tools in cancer
research. Despite their evolutionary distance, the gene
content of the mouse and human genomes has been largely
conserved through evolution [42], and most cancer pathways
are operative in both species [43]. The genomes of inbred
laboratorymouse strains are well-characterised andmice offer
a ‘clean’ system in which to test the biological effects of
genetic alterations or environmental effects; they are
essentially homozygous at every locus and are housed in a
controlled environment.
Sequencing of DNA from several tumour types that have
developed in mouse or man has recently revealed that human
tumours are more heterogeneous than their GEMM-derived
counterparts [44, 45]. The difference in complexity of mouse
and human tumours is likely due to a combination of factors.
Humans have a more varied diet and a different microbiome
compared to the laboratorymouse, and so their intestinal cells
are exposed to more exogenous genotoxins [46]. In addition,
these gene-environment interactions occur over a longer
period of time inman; the development of tumours in GEMM is
limited by the short lifespan of the mouse or by local research
ethics; for example the UK Home Office enforces a tumour size
limit of around 1 cm2. Furthermore, there is a lack of inter-
tumour heterogeneity of GEMM tumours because laboratory
mice are inbred and therefore lack the genetic heterogeneity
present in the outbred human population. Moreover, GEMM
tumours are often initiated and maintained by the same
genetic mutation of a strong cancer driver gene, which may
limit the number of pathways to tumourigenesis. While the
difference in complexity of tumours is advantageous when
applying a cross-species oncogenomics approach to cancer
gene validation [45], the lack of complexity of mouse tumours
poses a problem when trying to faithfully recapitulate the
human disease for pre-clinical studies. Some tumour types
can be treated in mouse models of cancer, but it is thought
that the heterogeneity of human tumours results in a greater
potential for resistance to therapy to develop, or for recurrence
after surgical resection. Nonetheless, GEMMs of CRC that
develop autochthonous intestinal tumours can better model
the dynamic interplay between intestinal tumour cells, stroma
and the immune system, as well as the response to therapy,
when compared with xenograft models.
Genetically modified mouse models of
late stage CRC—25 years in the making
Table 3 summarises some of the genetically modified mouse
models (GEMM) of CRC that have been developed over the last
25 years. The first key mouse model of CRC was the multiple
intestinal neoplasia (Min) mouse, which arose from a random
ethylnitrosourea (ENU) mutagenesis screen [47, 48]. The
ApcMin/+ mouse was subsequently recognised as a paralog for
human familial adenomatous polyposis (FAP) syndrome and
provided confirmation of the causal genemutation in sporadic
CRCs with 5q21 deletions [49]; later studies showed that
somatic inactivation of APC is observed in >80% of sporadic
CRCs [2].
Hereditary non-polyposis CRC (HNPCC) or Lynch Syn-
drome, is the most common inherited, autosomal dominant
CRC syndrome and accounts for around 3% of all CRCs.
HNPCC is most frequently caused by mutations in MLH1,
PMS1, PMS2, MSH2 or MSH6, (MutL Homolog 1, Post-Meiotic
Segregation Increased 1 and 2 and MutS Homolog 2 and 6,
respectively) that encode the enzymatic machinery of DNA
mismatch repair. As with sporadic cancers, intestinal cancers
from HNPCC patients have a high frequency of mutations in
APC, as well as KRAS, TP53 and TGFBR2 [50–52]. Further,
approximately 15% of sporadic CRCs display microsatellite
instability (MSI) secondary to impaired DNA mismatch repair,
frequently because of hypermethylation of the MLH1 pro-
moter [53]. One of the earliest models that had the potential
to recapitulate HNPCC was a homozygous Msh2/ deficient
mouse [54] (Table 3). Unfortunately, these mice were
predisposed to lymphomas, which limited their use as a
model of HNPCC. One way to restrict genetic modifications to
tissues of interest is to use a Cre-recombinase driven by a
tissue-specific promoter. Cre-recombinases catalyse recombi-
nation between two loxP sites that are situated in the introns
surrounding a critical exon(s) and result in excision of the
DNA between the sites. Using a conditional strategy that
results in expression of Cre recombinase from the Villin
promoter (intestinal specific gene) a Villin-Cre/Msh2LoxP
mouse was generated that resulted in intestinal adenomas
and adenocarcinomas in the absence of lymphoma [55]
(Table 3).
The short lifespan of theApcMin/+mouse limits the utility of
the model and it was thought that mice with fewer tumours
would live longer, and that if tumours were restricted to the
colon, they might progress to carcinoma and metastasise [56,
57]. A number of different Apc mutant mice with germline or
inducible cell-type specific conditional alleles of Apc were
developed (seeTable3 forexamplesandforanextensive review,
see [58]). Despite evidence of malignant transformation and
colonic invasion, aged Apc mutant mice did not develop
metastases, suggesting that to better model the later stages of
disease in the mouse, additional genetic mutations would be
required (Table 3). Apcmutant mice have been crossed to mice
with gene mutations found in later stage disease, including
TP53, KRAS, TGFBR2, FBXW7 and SMAD2-4, in an attempt to
generate more useful pre-clinical models. At best, double
mutants displayedmore adenocarcinomas, but themicedidnot
model the metastatic disease (see Table 3).
The many different Apc mutant mice that have been
created have led to greater understanding of the biology of
Apc, for example, to ascertain which protein domains and
functions of Apc are responsible for intestinal tumour
initiation and maintenance; it is widely accepted that Apc’s
role in activation of the Wnt pathway is the major contributor
to this process [59]. Apc mutant mice have also been used to
probe the effect of environmental factors and drugs on
intestinal tumourigenesis and stem cell specific Apc deletion
....Prospects & Overviews R. E. McIntyre et al.
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Table 3. Selection of genetically modified mouse models of colorectal cancer
Mouse
allele Rationale Strategy Advantages Disadvantages
ApcMin/+
[47, 48]
• N/A
• Ethylnitrosurea (ENU)
mutagenesis screen
• Tumour multiplicity
easily quantifiable
• Germline truncating
mutation (N terminus)
• Loss of heterozygosity
occurs at wildtype allele in
tumours
• Model of human familial
adenomatous polyposis (FAP)
syndrome and >80% of
sporadic CRCs contain
mutations [2, 4]
• Short-lived for rapid studies
• Developed hundreds of low-grade
adenomas
• Short-lived as tumour burden causes
obstruction, prolapse and bleeding
• Short life-span means that adenomas
do not acquire sufficient mutations to
progress to adenocarcinoma and
metastasise [56, 57]
• Tumours predominantly located in
small rather than large intestine
Msh2/
[54]
• Msh2 mutations
common in CRC
• Germline knock-out • Model of Hereditary non-
polyposis CRC (HNPCC) or
Lynch Syndrome (3% of all
CRCs)
•Msh2mutation in all cells of body and
mice are predisposed to lymphomas
Villin-Cre/
Msh2LoxP
[55]
• To restrict malignancy
to intestine to prevent
lymphoma
• Conditional
• Cre recombinasea
expressed from promoter of
intestinal specific gene (Villin)
• Developed intestinal
adenomas and
adenocarcinomas
• No deaths from lymphoma
• Do not develop metastases
Apc580S/580S
[64]
• To model advanced
CRC by restricting
tumours to colon and
reducing tumour
burden
• Conditional Adenoviral Cre
recombinasea is
administered through the
anus to inactivate Apc
• Live >1 year. • Do not develop metastases
• Developed two or three
intestinal adenomas
• Conditional allele (unactivated)
reduces Apc expression in all cells,
similar to Apcfl/fl [10], which results in
development of life-limiting
hepatocellular carcinomas by
14 months (REM unpublished
observations of Apc580S/580S)
• Some mice developed
adenocarcinomas
Apclox15/+;
Fabpl-Cre
[109]
• To model advanced
CRC by restricting
tumours to the colon
and reducing tumour
burden
• Conditional • Live >1 year. • Do not develop metastases
• Cre-recombinasea is
expressed in the distal small
intestinal and colonic
epithelia to inactivate Apc
• Developed two or three
intestinal adenomas
• Some mice developed
adenocarcinomas
ApcMin/+Trp53/
[110]
• To model advanced
CRC through addition
of cooperating gene
mutations
• Germline mutations in Apc
and Trp53
• Do not develop metastases
Apc2lox14/+
KrasLSL-G12D
and Fabpl-Cre
[111]
• To model advanced
CRC through addition
of cooperating gene
mutations
• Conditional • Developed more
adenocarcinomas than single
mutant (Apc or Kras alone)
control mice
• Do not develop metastases
• Cre-recombinasea is
expressed in the distal small
intestine/colonic epithelia
and results in constitutive
activation of K-Ras and
inactivation of Apc
Apc mutant
with disruption
of Tgfbr2, Smad2
or Smad4.
[112–114]
• To model advanced
CRC through addition
of cooperating gene
mutations
• Developed more
adenocarcinomas than single
mutant control mice.
• Do not develop metastases
ApcMin/+ Villin
Cre Fbxw7(DG)
[115]
• To model advanced
CRC through addition
of cooperating gene
mutations
• Germline mutation of Apc
• Conditional mutation of
Fbxw7
• Cre recombinasea
expressed from promoter of
intestinal specific gene (Villin)
• Decreased lifespan
• Increased tumour burden
• Fbxw7 null control mice
developed adenomas by 9-10
months of age
• Do not develop adenocarcinomas or
metastases
ApcCKO/CKO-
LSL-G12D;
Krastm4tyj/+
[62]
• To model advanced
CRC through addition
of cooperating
mutations. To restrict
tumours to the colon
and reduce tumour
burden
• Adenoviral Cre solution
administered via the anus to
simultaneously disrupt Apc
and activate K-ras
• Developed adenocarcinomas
after five months
• Developed metastases to
distant organs after six months
e.g. liver
• In vivo monitoring via
colonoscopy
• Labour intensive mouse surgery
required to clamp a section of colon to
deliver Adenoviral Cre solution to the
colon via the anus
CRC, Colorectal carcinoma.
aCre recombinases catalyse recombination between two loxP sites that are situated in the introns surrounding a critical exon(s) and result in excision of the
DNA between the sites.
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models lent support to the so-called ‘bottom-up’ model of
adenoma formation [60, 61].
One of the most promising models for both the
elucidation of the molecular events that support the
formation of distant metastases of colorectal cancer and
for preclinical investigations is a mouse that has simulta-
neous, inducible inactivation of Apc and activation of Kras
in the adult colon (Table 3). Six months after surgery 20%
of ApcCKO/CKO-LSL-Kras mice (G12D; Krastm4tyj/+ allele) mice
had developed metastases to distant organs such as the
liver [62]. It is important to note that expression of wild-
type Apc may be disrupted by introduction of conditional
alleles, which may elevate Wnt signalling levels in tissues
other than the intestine, and which appears to drive the
formation of life-limiting hepatocellular tumourigenesis
before the onset of intestinal tumourigenesis. For example
Apcfl/fl and Apc580S/580S mice show reduced expression of
Apc protein throughout their tissues (in the absence of Cre-
mediated recombination of alleles), and develop hepatocel-
lular carcinomas between 9 and 15months (our unpublished
observations ofApc580S/580Smice; [63, 64]). Thesefindingsmay
preclude the use of some mouse models in studies that aim to
understand the events that drive the metastasis of CRC to the
liver.
Mouse models of inflammatory bowel
disease and colorectal cancer
Inflammatory bowel diseases (IBD) such as ulcerative colitis
predispose patients to developing colorectal cancer as a result
of chronic inflammation. It is becoming apparent that these
tumours may develop through alternative TP53 dependent
routes compared with classical APC-driven tumours [65]. In
an attempt to model this disease process mice have been
generated that are predisposed to intestinal specific inflam-
mation, including Il-10/, Il-2null and Muc2/ deficient
strains [66, 67]. Colitis can also be experimentally induced
by the administration of dextran sulfate sodium (DSS) to
the drinking water of mice. In addition to mimicking IBD,
mice treated this way also produce intestinal tumours [68].
Azoxymethane (AOM) is another commonly used chemical
that predisposes to cancer experimentally. AOM is thought to
enable base mispairings, and when administered alone or in
combination with DSS, AOM reliably produces tumouri-
genesis in wild type mice [69].
Genetic screens in mice for validation of
cancer ‘driver’ genes
TCGA has identified genes that are frequently mutated in
many different types of malignancy (frequently referred to as
‘pan-cancer’ genes) suggesting that they are likely to
accelerate the process [70]. While these genes are obvious
targets for therapy, many are considered intractable
drug targets, including MYC and RAS. Within different cancer
sub-types there are cancer drivers that could be more
amenable to therapy, however it is difficult to make the
distinction between the ‘driver’ and ‘passenger’ genes
(mutations that drive disease progression and mutations that
do not) in patient specimens because of genetic, epigenetic
and environmental heterogeneity. In contrast, mouse models,
with their homogeneous genetic background and living
environment, can be an efficient tool for validating candidate
cancer genes (Figs. 1 and 2). Forward genetic screens in mice
using insertional mutagenesis have aided the identification or
validation of many drivers of cancer, the relevance of which is
assessed by comparing the candidates identified through
screening with mutations found in the human cancer
subtype [45].
One of the first insertional mutagenesis studies to identify
novel genetic drivers of intestinal tumourigenesis involved
restricting transposition to epithelial cells of the gastro-
intestinal tract using a Villin-Cre recombinase system [71].
Analysis of the common insertion sites for transposon in
neoplasms, adenomas and adenocarcinomas revealed that
80% of insertions fell in known CRC genes including
APC, FBXW7 (F-box and WD repeat domain containing 7),
PTEN (phosphatase and tensin homolog), and SMAD4,
thus validating the approach. The remainder, including
RSPO2 (R-spondin 2), had not been previously implicated in
the disease. R Spondin is a ligand for LGR4-6 receptors (LGR,
leucine-rich repeat containing G protein-coupled receptor),
which stimulate the canonical Wnt signalling pathway.
We now know that RSPO2 fusion genes occur in a subset of
colorectal carcinomas and are mutually exclusive with APC
mutations [7].
To identify mutations that cooperate with inactivation of
Apc and hyperactivation of the Wnt pathway, two independ-
ent teams of researchers mobilised the Sleeping Beauty
transposon in ApcMin/+ mice or conditional Apcfl/+ mice [6,
72]. The most frequently mutated gene (85%) in both studies
was Apc, consistent with the requirement for loss of
heterozygosity of Apc for intestinal tumour induction.
Interestingly, all three mutagenesis screens identified a
high number of insertions in the WW domain-containing
adaptor with coiled-coil gene (Wac), which is also mutated in
human cancers [6, 71–73]. WAC has recently been shown to
be required for activation of the cell-cycle checkpoint in
response to DNA damage suggesting that inactivation may
cause genomic instability [74]. Both insertional mutagenesis
studies of Apc mutant mice identified common insertions in
the voltage-gated potassium channel subunit Kcnq1 [6, 72].
Mutations in voltage-gated ion channel subunits have been
identified in a variety of human cancers, including colon, and
mounting evidence suggests that tumour cells have a
depolarised membrane voltage relative to surrounding tissue,
which could be exploited for therapy [75]. In support of this
finding, ApcMin/+Kcnq1/ double mutant mice developed
more intestinal adenomas than ApcMin/+ control mice, and
progression to aggressive adenocarcinomas was observed.
The authors went on to show that reduced KCNQ1 expression
correlated with poor survival in patients; however, the exact
mechanism of tumour suppression remains unknown [76].
These examples prove the utility of transposon-mediated
insertional mutagenesis for rapid validation of colorectal
cancer genes and for colorectal cancer gene discovery.
....Prospects & Overviews R. E. McIntyre et al.
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ApcMin/+ mice for early disease
biomarker discovery
Most screening strategies aimed at the early detection of
adenomas and CRC involve endoscopy, and thus have limited
applicability. Early detection of CRC is critical for disease
management, and so the identification of reliable, early
disease biomarkers would improve the outcome for many
patients. Mouse models that are predisposed to colorectal
tumour formation can be an efficient tool for early disease
biomarker discovery (Fig. 2). Since early detection of CRC is
critical for disease management, investigators have used mice
with germline Apc mutations, which model the initiation of
intestinal tumourigenesis, to screen for early disease bio-
markers. Clusterin was a ‘proof-of-principle’ for the cross-
species approach to biomarker discovery [77]. Upregulation of
clusterin was reported in adenomas from ApcMin/+ mice and
human tumours, and was recently shown to be highly-
expressed in intestinal stem cells [77, 78]. Secreted clusterin is
cytoprotective and its prosurvival function forms the basis of
the current Phase I/II clinical trials against prostate, lung, and
breast cancers [79].
Cross-species proteomics identifies early
disease biomarkers
Recent improvements in proteomic profiling methods, based
primarily on mass spectrometry, have allowed the detection
and identification of peptides in the blood and biological
fluids of cancer patients (Fig. 2). The plasma of tumour-
bearing Apc580S/D mice was screened by mass spectrometry,
and cathepsin B and D were found to be elevated compared
with control mice [80]. Cathepsins are involved in the
degradation of the basement membrane and extracellular
matrix, a key step in tumour invasion and metastasis.
Cathepsin B and cathepsin D are thought to associate with
tumour grade of CRC and survival suggesting they may be
useful biomarkers of the disease [80, 81]. Similarly, proximal
fluid proteome profiling of colon tumours from aged Apc15lox/+
Fabpl-Cre mice resulted in the identification of 192 proteins
that were more highly excreted by tumours relative to control,
including Chitinase 3-like 1 (Chi3l1) [82]. CHI3L1 is thought to
be involved in processes such as inflammation and tissue
remodeling, and was shown to be significantly elevated in the
sera of patients with adenomas and advanced adenomas
compared with control individuals [83].
Cross-species epigenomics identifies epigenetic
signatures of early disease
Epigenomic profiling of adenomas fromApcMin/+mice has also
been useful in the identification of patient relevant, early
disease biomarkers (Fig. 2). Immunoprecipitation of methy-
lated DNA followed by sequencing (known as ‘MeDIP-seq’)
identified regions of the genome were differentially methy-
lated [84]. These regions were mainly enriched for targets of
the Polycomb Repressive Complex, the subunits of which,
together with those for several DNA methyltransferase
complexes, were up-regulated in adenomas. This genome-
wide pattern was shown to be partly conserved in human
colon carcinomas, suggesting that an epigenetic signature is
established early and is retained during progression from
adenoma to carcinoma.
Target identification and validation
requires cancer cell lines, xenograft
models and GEMM
Not all cancer genes are essential for the sustained growth of
established tumours. In addition, tumours may have intrinsic
therapeutic resistance, which is believed to arise through
natural selection of a latent subclone within a tumour, or
acquired therapeutic resistance, which arises through acquis-
ition of a genetic mutation that allows the cancer cell to
survive in the presence of the therapeutic agent [15]. It is
therefore important to understand both the contribution of a
GENOMICS
EPIGENOMICSPROTEOMICS
TRANSCRIPTOMICS
point mutations
CNVs
small indels
differential expression
alternative splicing
RNA editing
gene fusions
DNA/mRNA methylation
gene silencing 
histone modifications
TF binding
phosphoproteome
biomarkers
differential expression
ubiquitome
gene activation
Figure 2. Cross-species comparative ‘omics’ approaches for color-
ectal cancer (CRC) gene, therapeutic target and early disease
biomarker discovery. Despite their evolutionary distance, the gene
content of the mouse and human genomes has been largely
conserved through evolution and most cancer pathways are
operative in both species. Sporadic, low-level mutagenesis of Apc
and Kras in the mouse colon results in a high frequency of invasive
adenocarcinomas and liver metastases. Furthermore, serial biopsies
of patient tumours is not realistic, but with the development of
mouse colonoscopes to guide biopsy collection, this is now a
possibility in mouse models. Cancer gene, therapeutic target and
biomarker discovery in patient specimens is challenging because of
genetic, epigenetic and environmental heterogeneity between
patients. Since many of these variables can be controlled for in the
inbred laboratory mouse, the comparison of human and mouse
primary and metastatic colorectal cancer genomes, transcriptomes,
epigenomes, and proteomes including ubiquitinomes, will provide a
powerful reductionist tool for identification of the molecular alter-
ations that drive CRC invasion and metastasis. CNV, copy number
variation; TF, transcription factor.
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disease target to tumourigenesis and the mechanisms by
which cancers evade targeted therapies. Here, we highlight
several recent approaches to the identification and validation
of novel therapeutic targets using mouse models of CRC.
Although genetic ablation or overexpression of potential
therapeutic targets in CRC cell lines before xenotransplantation
does not necessarily mimic pharmacological intervention, nor
does it mimic the biology of autochthonous tumours, it may
provideashortcut to targetvalidation(Fig. 1). Thisapproachhas
recently been useful for the validation of potential therapeutic
targets within the Wnt and TGFb pathways.
Targeting the Wnt pathway—reality or drug
discovery pipe dream?
Since theWnt–b-catenin signalling pathway is hyperactivated
in 93% of colorectal tumours and high Wnt activity defines
colon cancer stem cells, the Wnt pathway is the most
attractive therapeutic target for colorectal cancer [2, 29, 85].
Despite this, therapeutic agents that specifically target the
Wnt pathway have only recently entered clinical trials, and
none has yet been approved. The Wnt inhibitor XAV939
inhibits the poly(ADP)-ribosylating (PARP) enzymes tank-
yrase 1 and tankyrase 2, which interacts with AXIN (acts with
APC to destruct b-catenin and damper Wnt pathway activity)
to promote its ubiquitylation and degradation [86]. The
development of more selective and potent second-generation
tankyrase inhibitors is in progress, however their anti-tumour
potential may not be fully realised owing to their intestinal
toxicity in pre-clinical mouse models [9]. Rosenbluh and
colleagues took a more targeted approach to inhibition of the
Wnt pathway: they screened 85 cancer cell lines and found
that b-catenin active cancers are dependent on a signalling
pathway involving the transcriptional regulator YAP1 (Yes-
associated protein 1) [28]. YAP1 and the transcription factor
TBX5 were shown to form a complex with b-catenin, and
phosphorylation of YAP1 by the tyrosine kinase YES1 lead to
localisation of the complex to the promoters of anti-apoptotic
genes such as BIRC5. To determinewhether YAP1was required
for HCT116 xenograft growth they transfected cells with a
doxycycline-inducible shRNA to YAP1. Three weeks after
injection, tumour growth was restricted to 80% of control
animals, suggesting that the YAP1 pathway might be an
attractive therapeutic target [28]. Further studies will be
required to confirm whether this effect occurs in vivo, where
many endogenous ligands that are secreted by stromal cells
are known to modify Wnt pathway activity [22].
Targeting MYC—drugging the undruggable
The transcription factor Myc proto-oncogene protein (Myc) is
thought to be a target of the b-catenin–Tcf4 transcription
complex in CRC cells in vitro, in normal crypts in vivo and in
intestinal epithelial cells acutely transformed on in vivo
deletion of the Apc gene [59, 87, 88]. Array expression analysis
revealed that Myc is required for the majority of b-catenin–
Tcf4 transcription complex gene activation following Apc loss
in mice. While Myc is required for the formation of intestinal
crypts, it is dispensable for homeostasis of the adult intestinal
epithelium [89]. Using a combination of conditional mouse
models, it was shown that simultaneous inactivation of Myc
and Apc completely ablated tumour development in mice
despite high levels of nuclear b-catenin in the intestinal
epithelium [90]. Multiple cancer-associated single-nucleotide
polymorphisms (SNPs) have been mapped to conserved
sequences within a 500-kilobase region upstream of the
MYC oncogene on human chromosome 8q24, and mice
lacking a Myc enhancer (Myc-335) that includes human SNP
rs6983267 are resistant to intestinal tumours induced by the
ApcMin mutation [91]. While these studies have established
Myc as a critical mediator of the early stages of intestinal
neoplasia following Apc loss, it has not yet been possible to
pharmacologically regulate Myc. Instead, a selective small-
molecule BET bromodomain inhibitor, JQ1, inhibits proteins
that are regulatory factors for Myc [92]. Treatment with JQ1
resulted in genome-wide downregulation of Myc-dependent
target genes, reduced proliferation and had anti-cancer
properties in a mouse model of multiple myeloma, a Myc-
dependent hematologic malignancy, suggesting that JQ1 may
perform similarly in mouse models of colorectal cancer.
Pharmacological inhibition of TGFBR1 inhibits
metastasis formation
A large proportion of CRCs display mutational inactivation
of the TGFb pathway. However, paradoxically, they are
characterised by elevated TGFb production. In other cancer
types, such as breast or prostate, which retain a functional
TGFb signalling pathway, TGFb induces a variety of
prometastatic programmes that range from induction of
epithelial-to-mesenchymal-like transition (or ‘EMT’) to expres-
sion of genes that allow colonisation of foreign organs [93].
During 10 years of follow-up after surgical resection of
colorectal tumours, only patients with medium or high TGFb
expression in the primary tumour suffered cancer recurrence,
whereas all patients bearing TGFb -low stage I, II and III
tumours remained disease-free [94]. When Nude mice were
inoculated with KM12L4a cells that overexpressed TGFb,
nearly all developed lung and/or liver metastasis, whereas
only one third of control mice developed metastases. It is
thought that the metastatic KM12L4aTGFB1 cells were conferred
a survival advantage by suppressing apoptotic stimuli
encountered during organ colonization. Moreover, inhibition
of TGFBR1 has been shown to inhibit metastasis formation in
multiple xenograft models [94, 95]. Since the mechanism is
thought to involve cross-talk between tumour and stromal
cells, it will be important to show that this regulation occurs in
autochthonously occurring liver metastases of CRC, such as
those that arise in the conditional ApcCKO/CKO/KrasG12D colon
cancer model [62].
Isograft models for validating the role of the
immune system in CRC
In a recent study, Bindea and colleagues examined the spatio-
temporal dynamics of 28 different immune cell types (the
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‘immunome’) that were infiltrating colorectal tumours were
analysed by whole-genome expression, PCR arrays and
multicolored immunohistochemistry [96]. The analysis
revealed that patients with elevations in genes related to
MHC-II, B cell co-stimulation, T cells and Tfh cells experience
increased survival. One chemokine in particular, CXCL13, and
one cytokine, IL-21, positively correlated with disease-free
survival. Bindea and colleagues showed growth acceleration
of MC38 isografts in Cxcr5/ mice (CXCR5 is the receptor for
CXCL13) compared to control, and rejection of tumour cells
when recombinant CXCL13 was injected into the colonic
submucosa of wild-type mice before transplantation [96].
These data confirmed the prognostic value of CXCL13 in
assessing CRC tumour burden, and prove the utility of mouse
models in the validation of disease biomarkers.
Conclusions and outlook
In combination with studies of CRC cell lines and organoid
models, mouse models of late-stage CRC will help us to build a
comprehensive picture of the molecular alterations that drive
tumour formation and disease progression, through cross-
species analysis of the genomes, epigenomes, transcriptomes,
proteomes and even immunomes of cancers of mice and men.
Mouse models will be critical for reductionist approaches that
aim to validate the cancer drivers frommutations identified by
the TCGA.
Human CRC is the result of interactions between genes,
including those involved in host immunity, and the environ-
ment, including diet and the microbiome [97, 98]. The mouse
affords the ability to investigate the effects of each of these
factors independently of each other, which is simply not
possible in man. However, recent studies have shown that
‘pound for pound’, the average mouse tumour is less complex
than the average human tumour. These sequencing studies,
together with the knowledge that lifestyle factors strongly
influence the chances of getting cancer, suggest that the
relative simplicity of GEMM tumours is due to the lack of gene-
environment interactions in the controlled environment of the
laboratory mouse. There is a reasonable body of evidence to
suggest that high red meat intake and alcohol consumption
are risk factors for CRC, but we are probably only just
beginning to understand how our environment affects the
course of disease [99]. Modelling the full heterogeneity of
human tumours will be required to help tackle the problems of
therapeutic resistance and recurrence after surgical resection
in CRC; thismight be better achieved by generating GEMM that
combine a genetic predisposition to CRC with a diet rich in
foods associated with increased risk of CRC.
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